Pranav Dorbala

Pranav Dorbala

Auto-generated profile, based on publicly available information

Pranav Dorbala

Brigham and Women’s Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Circulation: Heart Failure
Verified
Journal Article
Closed access
LBLeo F. Buckley
Leo F. Buckley
AAAli M. Agha
Ali M. Agha
PDPranav Dorbala
Pranav Dorbala
BCBrian L. Claggett
Brian L. Claggett
BYBing Yu
Bing Yu
ASAmil M. Shah
Amil M. Shah
BACKGROUND: MMP (matrix metalloproteinase)-2 participates in extracellular matrix regulation and may be involved in heart failure (HF), atrial fibrillation (AF), and coronary heart disease. METHODS: Among the 4693 ARIC study (Atherosclerosis Risk in Communities) participants (mean age, 75±5 years; 42% women) without prevalent HF, multivariable Cox proportional hazard models were used to estimate associations of plasma MMP-2 levels with incident HF, HF with preserved ejection fraction (≥50%), HF with reduced ejection fraction (<50%), AF, and coronary heart disease. Mediation of the association between MMP-2 and HF was assessed by censoring participants who developed AF or coronary heart disease before HF. Multivariable linear regression models were used to assess associations of MMP-2 with measures of left ventricular and left atrial structure and function. RESULTS: Compared with the 3 lower quartiles, the highest MMP-2 quartile associated with greater risk of incident HF overall (adjusted hazard ratio, 1.48 [95% CI, 1.21–1.81]), incident HF with preserved ejection fraction (1.44 [95% CI, 1.07–1.94]), incident heart failure with reduced ejection fraction (1.48 [95% CI, 1.08–2.02]), and incident AF (1.44 [95% CI, 1.18–1.77]) but not incident coronary heart disease (0.97 [95% CI, 0.71–1.34]). Censoring AF attenuated the MMP-2 association with HF with preserved ejection fraction. Higher plasma MMP-2 levels were associated with larger left ventricular end-diastolic volume index, greater left ventricular mass index, higher E/e′ ratio, larger left atrial volume index, and worse left atrial reservoir and contractile strains (all P <0.001). CONCLUSIONS: Higher plasma MMP-2 levels associate with diastolic dysfunction, left atrial dysfunction, and a higher risk of incident HF and AF. AF is a mediator of MMP-2–associated HF with preserved ejection fraction risk.

16 January 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
IAIman Ahmed Fathalla Aboelsaad
Iman Ahmed Fathalla Aboelsaad
BCBrian L Claggett
Brian L Claggett
VLVictoria Lamberson
Victoria Lamberson
PDPranav Dorbala
Pranav Dorbala
KMKunihiro Matsushita
Kunihiro Matsushita
LBLeo F Buckley
Leo F Buckley
Aims: Hepcidin regulates plasma and tissue iron levels. We studied the association of hepcidin levels with the risk of incident heart failure (HF) and cardiac dysfunction in older adults. Methods and results: We included adults from the ongoing, longitudinal Atherosclerosis Risk in Communities (ARIC) study, who were free from prevalent anaemia and HF at Visit 5 (2011–13) and had available hepcidin and covariate data. Associations of plasma hepcidin levels with overall adjudicated incident HF, HF with reduced ejection fraction (HFrEF), and HF with preserved ejection fraction (HFpEF) were assessed using multivariable Cox proportional hazards regression models. Cross-sectional associations of hepcidin with echocardiographic measures of cardiac structure and function were estimated using multivariable linear regression models. The mean age was 75 ± 5 years old, and 56% were women. In fully adjusted models, lower hepcidin levels were associated with a higher risk of overall incident HF [hazard ratio [HR] [95% confidence interval (CI) per 50% lower hepcidin]: 1.15 [1.05–1.26]; P = 0.003] and HFpEF [HR (95% CI): 1.25 (1.10–1.42); P = 0.001]. Plasma hepcidin level was not significantly associated with the risk of incident HFrEF [HR (95% CI): 1.08 (0.94–1.24); P = 0.30]. Lower hepcidin levels were associated with higher E wave (P = 0.046), higher E/e′ ratio (P = 0.002), higher left atrial volume index (P = 0.005), and higher pulmonary artery systolic pressure (P = 0.02). Conclusion: In community-dwelling older adults without anaemia, lower plasma hepcidin levels associate with a higher risk of incident HF (particularly HFpEF) and diastolic dysfunction.

1 January 2023 in Biomicrofluidics
Verified
Journal Article
Closed access
PDF file
PDP. Delgado
P. Delgado
OOO. Oshinowo
O. Oshinowo
MFM. E. Fay
M. E. Fay
CLC. A. Luna
C. A. Luna
ADAnjana Dissanayaka
Anjana Dissanayaka
DMD. R. Myers
D. R. Myers
Integrating microfluidic mixers into lab-on-a-chip devices remains challenging yet important for numerous applications including dilutions, extractions, addition of reagents or drugs, and particle synthesis. High-efficiency mixers utilize large or intricate geometries that are difficult to manufacture and co-implement with lab-on-a-chip processes, leading to cumbersome two-chip solutions. We present a universal dry-film microfluidic mixing sticker that can retrofit pre-existing microfluidics and maintain high mixing performance over a range of Reynolds numbers and input mixing ratios. To attach our pre-mixing sticker module, remove the backing material and press the sticker onto an existing microfluidic/substrate. Our innovation centers around the multilayer use of laser-cut commercially available silicone-adhesive-coated polymer sheets as microfluidic layers to create geometrically complex, easy to assemble designs that can be adhered to a variety of surfaces, namely, existing microfluidic devices. Our approach enabled us to assemble the traditional yet difficult to manufacture “F-mixer” in minutes and conceptually extend this design to create a novel space-saving spiral F-mixer. Computational fluid dynamic simulations and experimental results confirmed that both designs maintained high performance for 0.1 < Re < 10 and disparate input mixing ratios of 1:10. We tested the integration of our system by using the pre-mixer to fluorescently tag proteins encapsulated in an existing microfluidic. When integrated with another microfluidic, our pre-mixing sticker successfully combined primary and secondary antibodies to fluorescently tag micropatterned proteins with high spatial uniformity, unlike a traditional pre-mixing “T-mixer” sticker. Given the ease of this technology, we anticipate numerous applications for point-of-care devices, microphysiological-systems-on-a-chip, and microfluidic-based biomedical research.

20 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
KSKhaled Shelbaya
Khaled Shelbaya
BCBrian Claggett
Brian Claggett
PDPranav Dorbala
Pranav Dorbala
HSHicham Skali
Hicham Skali
SSScott D. Solomon
Scott D. Solomon
ASAmil M. Shah
Amil M. Shah
Background: American Heart Association and American College of Cardiology guidelines articulate 4 aortic stenosis ( AS ) stages to highlight its progressive nature, but limited data exist on cardiac alterations in sub‐severe stages. Methods: ARIC (Atherosclerosis Risk in Communities) study participants with protocol echocardiography at Visit 5 ( V5 ; 2011–2013) and free of aortic valve ( AV ) replacement or cardiovascular disease were classified by ACC / AHA AS stages at V5 and Visit 7 ( V7 ; 2018–2019). AS stage progression was defined as AV replacement or hospitalization, or a higher stage at V7 . Associations of AS stage at V5 and AS stage progression from V5 to V7 with cardiac structure and function were assessed using multivariable linear regression. Associations of extra‐ AV cardiac abnormality categories with AS stage progression were assessed by multivariable logistic regression. Results: Of 5206 V5 participants (age 75±5 years, 40% men), AS stages A and B at V5 were associated with greater left ventricular wall thickness, mass, and filling pressure measures at both V5 and V7 compared with Stage 0. Among 1562 participants with assessable AS stage at V7 , AS stage progression occurred in 370 and was associated with greater worsening of these measures (all P <0.02). The presence of both left ventricular and left atrial extra‐ AV abnormalities was associated with greater likelihood of AS stage progression ( odds ratio 1.7 [95% CI, 1.2–2.6], P =0.009). Conclusions: Early AS stages are associated with greater left ventricular mass and diastolic dysfunction, and AS stage progression is associated with worsening of these measures. The presence of both left ventricular and left atrial extra‐ AV abnormalities is associated with a greater likelihood of early AS stage progression.

1 May 2021 in JACC
Verified
Journal Article
Closed access
MMMajed Mazen Malak
Majed Mazen Malak
PHPavel Hushcha
Pavel Hushcha
SJS. Hammad Jafri
S. Hammad Jafri
GBGisele Bousquet
Gisele Bousquet
LCLexie Cabral
Lexie Cabral
HSHicham Skali
Hicham Skali